Evidence map›Paper›PMID 39474146›Full record

ReviewChemical & biomedical imaging2024

Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.

Xin Ji, Xin Chen, Kexin Li, Zhihao Zhang, Lijun Tang, Tiannv Li, Feng Han, Hao Hong, Tao Zhang

Abstract readReview
In one paragraph

Review in Chemical & biomedical imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xin JiDepartment of Radiopharmaceuticals, Nuclear Medicine Clinical Translation Center, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
Xin ChenDepartment of Radiopharmaceuticals, Nuclear Medicine Clinical Translation Center, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
Kexin LiDepartment of Radiopharmaceuticals, Nuclear Medicine Clinical Translation Center, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
Zhihao ZhangDepartment of Radiopharmaceuticals, Nuclear Medicine Clinical Translation Center, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
Lijun TangDepartment of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Tiannv LiDepartment of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Feng HanDepartment of Radiopharmaceuticals, Nuclear Medicine Clinical Translation Center, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.ORCID https://orcid.org/0000-0002-7800-9852
Hao HongState Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing 210093, China.ORCID https://orcid.org/0000-0002-9730-9367
Tao ZhangDepartment of Radiopharmaceuticals, Nuclear Medicine Clinical Translation Center, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.ORCID https://orcid.org/0000-0002-0920-0151

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the flourishing development of precision medicine, theranostics, generally recognized as the integration of diagnosis and treatment, has emerged as a prominent trend in clinical research. However, theranostics primarily emphasizes the end result of integration, without providing sufficient details on how precise diagnosis and synergetic individualized treatment could be achieved and what clinical challenges could be effectively addressed in clinical practice. Molecular probe technology provides a robust method to bridge the gap between theory and practice. Through meticulous design of the chemical structure, imaging labels or drugs were conjugated to tumor-targeting peptides, antibodies, or inducers to form molecular probes, which allow a seamless switch between targeted intervention and targeted imaging with consistency in time, space, and biodistribution. Thus, this review proposes a concept called "molecular eye", which refers to a comprehensive system for precise diagnosis and treatment of major clinical diseases based on molecular probe technology. This medical system emphasizes the chemical basis of probe development and optimization, which can provide precise actionable information for clinical decision making, allow molecular-targeted therapy, expand the indications of old therapy, and accelerate the regulatory approval of molecular drugs. "Molecular eye" resembles the piercing eye of the Monkey King, which can detect previously "invisible" diseases and facilitate disease diagnosis, treatment, real-time evaluation, and pathology research, guiding drug development. The emergence of the "molecular eyes" will provide opportunities and challenges in the fields of clinical practice and medical research and propel the progression of contemporary medicine toward precision medicine.

Identifiers

PMID39474146
PMCPMC11504603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.